Prescient Therapeutics (ASX: PTX) developing novel personalised therapies against a range of cancers (w/ Steven Yatomi-Clarke)

Small Caps - A podcast by Small Caps

Try Bookbeat 60! days for free, click here

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

 Sponsored

Categories:

Business

Prescient Therapeutics (ASX: PTX) managing director and chief executive officer Steven Yatomi-Clarke joins Small Caps to discuss the company's novel approach to treating cancer using targeted and cellular therapy. Prescient Therapeutics is the only ASX-listed company developing CAR-T technology, which is a type of cellular therapy that reprograms a cancer patient's immune cells to recognise and destroy cancer. The clinical stage oncology company recently announced it will be teaming up with the Peter MacCallum Cancer Centre to advance its CAR-T therapy.